NewAmsterdam Pharma Company N.V.NAMSNASDAQ
Loading
R&D Expense Growth Under PressureDecelerating
Percentile Rank0
Studio
Year-over-Year Change

Year-over-year research & development expense growth

Percentile
P0
Near historical low
vs 3Y Ago
0x
Contraction
Streak
4 yr
Consecutive declineDecelerating
PeriodValue
2025-6.32%
2024-5.03%
202383.79%
2022199.39%
2021486.36%
20200.00%